PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma.

Nnamdi Eze,Ju-Whei Lee,Dong-Hua Yang,Fang Zhu,Veronique Neumeister,Teresa Sandoval-Schaefer,Ranee Mehra,John A Ridge,Arlene Forastiere,Christine H Chung,Barbara Burtness

Oral Oncology（2019）

引用 34|浏览2

暂无评分

摘要

•Immunofluorescence determined a PTEN cutpoint with 100% sensitivity and specificity.•PTEN loss and PIK3Ca hotspot mutation were mutually exclusive.•Cetuximab improved PFS in patients with PTEN expression/no PIK3Ca mutation (p = 0.0502).•PTEN expression correlates with PFS for cetuximab-treated patients (HR = 0.35, p = 0.008).

查看译文

关键词

Head and neck cancer,Cetuximab,PTEN,Biomarkers

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要